Citations

Clear

3042 citation(s) found for "Kumar, S".

A hitchhiker’s guide to cerebrospinal fluid biomarkers for neuro-oncology
Riviere-Cazaux, Cécile , Keough, Michael B. , Schulz, Sebastian C, Warrington, Arthur E. , Ruff, Michael W. , Sanai, Nader , Campian, Jian , Kizilbash, Sani H. , Zadeh, Gelareh , Khasraw, Mustafa , Kessler, Tobias , Cahill, Daniel P. , Mansouri, Alireza , Kizilbash, Sani H , Zuccato, Jeffrey , Kumar, Rahul Robaish , Schulz, Sebastian C, Ellingson, Benjamin M. , Parney, Ian F. , Khasraw, Mustafa , Sener, Uğur , Mansouri, Alireza , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | December 27, 2024 | Volume: 27 | Issue: 5 | Pages: 1165-1179

10.1093/neuonc/noae276 | PMID 39786477 Get It

Abstract Cerebrospinal fluid (CSF) has emerged as a valuable liquid biopsy source for glioma biomarker discovery and validation. CSF produced within the ventricles circulates through the subarachnoid space, where the composition of glioma-derived analytes is influenced by the proximity and anatomical location of sampling relative to tumor, in addition to underlying tumor biology. The substantial gradients observed between lumbar and intracranial CSF compartments for tumor-derived analytes underscore the importance of sampling site selection. Moreover, radiographic features, such as tumor-CSF contact and blood-brain barrier disruption, are critical covariates that may affect biomarker detection and the abundance of plasma-derived analytes in CSF, respectively. Longitudinal intracranial CSF sampling, enabled by access devices like Ommaya reservoirs, may offer a window into treatment response and disease progression, though variability in analyte yield, sample volumes, and the dynamic effects of surgical resection pose challenges. This review critically evaluates the anatomic, radiographic, and longitudinal factors, or “time-space continuum,” that impact glioma CSF biomarker abundance. Practical considerations for longitudinal CSF biobanking, including access device placement and collection, are also reviewed. Key takeaways and recommendations for CSF glioma biomarker discovery and validation are provided as a “hitchhiker’s guide” based on our collective experience, along with resources for investigators aiming to develop CSF biobanking at their institutions.
Optimizing Ewing Sarcoma and Osteosarcoma Biopsy Acquisition: A Children’s Oncology Group Bone Tumor Committee Consensus Statement
Dietz, Matthew S. , Al‐Ibraheemi, Alyaa , Craig, Brian T. , Dasgupta, Roshni, Geller, David S. , Shulman, David S. , Whiteway, Susan L. , Slotkin, Emily K. , Albert, Catherine M. , Montgomery, Nicole I. , Sandberg, Jesse K. , Grier, Holcombe E. , Krailo, Mark , Isakoff, Michael S. , Rubin, Elyssa, Lawlor, Elizabeth R. , DuBois, Steven G. , Grohar, Patrick J. , Janeway, Katherine A. , Roberts, Ryan D. , Dasgupta, Roshni , Ahmed, Safia K. , Dasgupta, Roshni , Roberts, Ryan D , Davis, Jessica L. , Hawkins, C. Matthew , Cohen‐Gogo, Sarah , Gupta, Ajay Kumar , Heske, Christine M. , Indelicato, Daniel J. , Mascarenhas, Leo , Binitie, Odion , Reed, Damon R. , Bailey, Kelly M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 27, 2024 | Volume: 23 | Issue: 1 | Pages: No page available

10.6004/jnccn.2024.7063 | PMID 39729709 Get It

Trends in diagnostic biopsy sample collection approaches for primary bone sarcomas have shifted in the past 2 decades. Although open/incisional biopsies used to be the predominant approach to obtain diagnostic material for Ewing sarcoma and osteosarcoma, image-guided core needle biopsies have increased in frequency and are safe for patients. These procedures are less invasive and reduce recovery times but have potential limitations. The quantity and quality of tissue obtained through these procedures vary between institutions. Acquired viable tissue volumes can be low, limiting the conduct of downstream expanded clinical workup, molecular analyses, and research. Patients with advanced Ewing sarcoma and osteosarcoma continue to have overall poor outcomes despite dose-intensive cytotoxic chemotherapy. The biology of treatment resistance is not currently well understood, partly due to limited availability of relevant tissue to study. There is a need for access to quality tumor specimens for molecular and other analyses to identify high-risk tumor subsets and drive discovery to improve patient outcomes. Given broad variability in bone tumor tissue procurement and processing across member institutions, the Children’s Oncology Group Bone Tumor Committee convened a multidisciplinary group of experts to outline the current and near-future tissue needs for optimal clinical care and access to research platforms. The goal of this working group was to provide high-level guidance on biopsy practices that safely meet these evolving needs. Harmonizing tissue collection practices is paramount to improving the care of children, adolescents, and young adults diagnosed with Ewing sarcoma and osteosarcoma.
Semaglutide-Associated Gastric Pneumatosis
Turunen, Arto , Coombs, Reilly A. , Garg, Sushil Kumar , Turunen, Andrew M.

Mayo Clinic

ACG Case Reports Journal | December 27, 2024 | Volume: 12 | Issue: 1 | Pages: e01579

10.14309/crj.0000000000001579 | PMID 39734391 Get It

ABSTRACT Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.
Longitudinal Glioma Monitoring via Cerebrospinal Fluid Cell-Free DNA
Riviere-Cazaux, Cécile , Dong, Xiaoxi , Mo, Wei , Kumar, Rahul , Dai, Chao , Carlstrom, Lucas P. , Munoz-Casabella, Amanda , Nesvick, Cody L. , Andersen, Katherine M., Hoplin, Matthew D. , Canaday, Nicholas, Jusué-Torres, Ignacio , Malik, Noor , Campian, Jian L., Ruff, Michael W. , Uhm, Joon H. , Eckel‐Passow, Jeanette E. , Kizilbash, Sani H. , Warrington, Arthur E. , Jenkins, Robert B. , Du, Pan , Jia, Shidong , Ghadimi, Keyvan , Nesvick, Cody L , Andersen, Katherine M , Hoplin, Matthew D , Canaday, Nicholas , Jusue-Torres, Ignacio , Malik, Noor , Campian, Jian L , Ruff, Michael W , Uhm, Joon H , Eckel-Passow, Jeanette E , Kaufmann, Timothy J , Routman, David M , Kizilbash, Sani H , Sener, Ugur , Warrington, Arthur E , Jenkins, RB , Du, Pan , Jia, Shidong , Burns, Terry C , Kumar, Rahul , Kaufmann, Timothy J. , Routman, David M. , Sener, Uğur , Burns, Terry C.

Mayo Clinic

Clinical Cancer Research | December 23, 2024 | Volume: 31 | Issue: 5 | Pages: 881-889

10.1158/1078-0432.ccr-24-1814 | PMID 39715486 Get It

Abstract Purpose: Current methods for glioma response assessment are limited. This study aimed to assess the technical and clinical feasibility of molecular profiling using longitudinal intracranial cerebrospinal fluid (CSF) from patients with gliomas. Experimental Design: Adults with gliomas underwent longitudinal intracranial CSF collection via Ommaya reservoirs or ventriculoperitoneal shunts. Cell-free DNA (cfDNA) was extracted and analyzed using PredicineCARE for cancer variant profiling and/or PredicineSCORE for low-pass whole-genome sequencing. Results: Five patients (two females and three males; median age, 40 years; range, 32–64 years) underwent longitudinal intracranial CSF collection via Ommaya reservoirs (n = 4) or ventriculoperitoneal shunts (n = 1). In total, 47 CSF samples were obtained (median volume, 4.00 mL; 0.5–5 mL). Forty-one samples (87.2%) yielded sufficient cfDNA for testing. Patient-specific tumor-associated variant allelic frequencies (VAF), and thus tumor fraction, decreased in pre- versus postchemoradiation samples, including through pseudoprogression. These also increased with radiographic progression in three patients, although identifying the time of definitive disease progression from MRIs was a significant limitation. In two patients with isocitrate dehydrogenase (IDH)–mutant gliomas, decreasing IDH1 VAF after resection and chemoradiation correlated with decreased CSF D-2-hydroxyglutarate levels (0.64× and 0.62×, respectively, for the first patient and 0.01× and 0.07× for the other patient), although D-2-hydroxyglutarate and IDH1 VAF were not concordant in one patient thereafter. Moreover, the copy-number burden decreased below the limit of quantification during treatment and increased above the limit at progression. Conclusions: Longitudinal intracranial CSF cfDNA can be obtained in patients with gliomas during their disease course. However, before deploying this technique, numerous questions and challenges should be answered.
Risk-adapted treatment for multiple myeloma: assessing the current potential and a roadmap for the future
Zanwar, Saurabh , Kumar, Shaji

Mayo Clinic

Leukemia & Lymphoma | December 22, 2024 | Volume: 66 | Issue: 4 | Pages: 573-583

10.1080/10428194.2024.2443550 | PMID 39709634 Get It

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
Sandahl, Tyler B. , Soefje, Scott A. , Ailawadhi, Sikander , Parrondo, Ricardo , Lin, Dee , Wu, Bingcao , Calay, Ediz S. , Silvert, Eli , Carpenter, Corinne , Wagner, Tyler E. , Fowler, Jessica , Hester, Laura , Rangarajan, Nivedita , Marshall, Alexander Mclean, Stoy, Patrick, Gifkins, Dina , Kumar, Shaji , Ailawadhi, Sikander , Parrondo, Ricardo D , Lin, Dee , Wu, Bingcao , Calay, Ediz S , Wagner, Tyler E , Hester, Laura , Murugadoss, Karthik , Gifkins, Dina , Lin, Yi , Kumar, Shaji K , Soefje, Scott A , Sandahl, Tyler B , Fonseca, Rafaël , Kim, Nina , Fowler, Jessica, Murugadoss, Karthik , Marshall, Alexander, Lin, Yi

Mayo Clinic

JCO Oncology Practice | December 20, 2024 | Volume: 21 | Issue: 5 | Pages: 702-709

10.1200/op-24-00489 | PMID 39705632 Get It

PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.
Cumulative deficits frailty index and relationship status predict survival in multiple myeloma
Abdallah, Nadine , Dizona, Paul, LaPlant, Betsy, Schaeferle, Gavin, Aug, Sarah, Weivoda, Megan , Buadi, Francis K. , Warsame, Rahma , Lacy, Martha Q. , Hayman, Suzanne R. , Kumar, Shaji , Menser, Terri , Weivoda, Megan , Dispenzieri, Angela , Buadi, Francis K , Warsame, Rahma , Cook, Joselle M , Lacy, Martha Q , Gertz, Morie A , Kumar, Shaji K , Kumar, Amanika , Dispenzieri, Angela , Cook, Joselle , Gertz, Morie A. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | December 18, 2024 | Volume: 9 | Issue: 5 | Pages: 1137-1146

10.1182/bloodadvances.2024014624 | PMID 39693516 Get It

Abstract Several tools have been proposed for assessing frailty in multiple myeloma (MM), but most are based on clinical trial data sets. There are also limited data on the association between frailty and patient-reported outcomes and on the prognostic value of social determinants of health. This study evaluates the prognostic impact of frailty, based on the cumulative deficit frailty index (FI), and relationship and socioeconomic status (SES) in patients with newly diagnosed MM. This retrospective study included 515 patients with MM seen at Mayo Clinic (Rochester, MN) at diagnosis between 2005 and 2018. The FI was calculated using patient-reported data on activities of daily living and comorbidity data, with items scored as 0, 0.5, or 1, in which 1 indicated a deficit. The FI was calculated by dividing the total score by the number of nonmissing items. Frailty was defined as FI ≥0.15; 61% were nonfrail, and 39% were frail. Frailty and nonmarried/relationship status were associated with higher disease stage, decreased the likelihood of early transplantation, and independently associated with decreased survival. SES was not independently associated with survival. Frail patients reported worse scores for fatigue, pain, and quality of life. Approximately a quarter of patients had a deterioration in frailty status at 3 to 12 months, and &lt;10% had improvement. In conclusion, a cumulative deficit FI was associated with higher symptom burden and decreased survival in a real-world cohort of patients with newly diagnosed MM. Frailty status is dynamic and should be reassessed during treatment. Social support has prognostic value and should be evaluated in clinical practice.
Targeted therapy‑associated cardiotoxicity in patients with stage‑IV lung cancer with or without cardiac comorbidities
Peng, Yanmei , Li, Dong , Gu, Zhong, Kosuru, Nikhila, Yu, Nathan Y. , Wang, Zhichao , Leventakos, Konstantinos , Ernani, Vinicius , Wampfler, Jason A. , Luo, Yung‐Hung , Kumar, Ashok, Yang, Ping

Mayo Clinic

Oncology Reports | December 18, 2024 | Volume: 53 | Issue: 2 | Pages: No page available

10.3892/or.2024.8858 | PMID 39704259 Get It

Resting-State Functional MRI: Current State, Controversies, Limitations, and Future Directions— AJR Expert Panel Narrative Review
Vachha, Behroze , Pillai, Jay J. , Tanabe, Jody , Sair, Haris I. , Pillai, Jay J , Kumar, Vinodh A. , Shimony, Joshua S.

Mayo Clinic

American Journal of Roentgenology | December 11, 2024 | Volume: 225 | Issue: 3 | Pages: No page available

10.2214/ajr.24.32163 | PMID 39660823 Get It

What is the ideal approach—doublet, triplet, or quadruplet(s)?
Kumar, Shaji

Mayo Clinic

Hematology | December 6, 2024 | Volume: 2024 | Issue: 1 | Pages: 551-560

10.1182/hematology.2024000581 | PMID 39644003 Get It

Abstract Significant progress has been made in the treatment of multiple myeloma (MM), with the introduction of several new drugs with different mechanisms of action. The treatment of newly diagnosed MM has evolved dramatically with the development of highly effective combinations that include 1 or more of the new drugs. Despite the continuing improvement in the overall survival of patients with MM, nearly a quarter of the patients have significantly inferior survival, often driven by a combination of factors, including tumor genetics and host frailty. The focus of initial therapy remains rapid control of the disease with reversal of the symptoms and complications related to the disease with minimal toxicity and a reduction in early mortality. The selection of the specific regimen, to some extent, depends on the ability of the patient to tolerate the treatment and the underlying disease risk. It is typically guided by results of randomized clinical trials demonstrating improvements in progression-free and/or overall survival. While increasing risk calls for escalating the intensity of therapy by using quadruplet combinations that can provide the deepest possible response and the use of autologous stem cell transplant, increasing frailty calls for a reduction in the intensity and selective use of triplet or doublet regimens. The choice of subsequent consolidation treatments and maintenance approaches, including duration of treatment, also depends on these factors, particularly the underlying disease risk. The treatment approaches for newly diagnosed myeloma continue to evolve, with ongoing trials exploring bispecific antibodies as part of initial therapy and CAR T cells for consolidation.